Programs, the Department of Human Services, the Department of
Health, the Pennsylvania Board of Probation and Parole and
the Pennsylvania Commission on Crime and Delinquency.
(4) Promulgate any rules and regulations necessary to
implement this chapter.
§ 4606. Prior authorization.
Long acting injectable naltrexone shall not be subject to
prior authorization by any Medicaid managed care plan operating
under contract with the Commonwealth. Within 90 days of the
effective date of this section, the Department of Human Services
shall issue a bulletin notice to prohibit Medicaid managed care
plans from requiring prior authorization for the use of long
acting injectable naltrexone.
§ 4607. Report to General Assembly.
By June 30, 2016, the department shall issue a report to the
Judiciary Committee of the Senate and the Appropriations
Committee of the Senate and the Judiciary Committee of the House
of Representatives and the Appropriations Committee of the House
of Representatives evaluating the effectiveness of the program.
The report shall include:
(1) The number of eligible offenders to whom long-acting
injectable naltrexone was administered.
(2) The number of eligible offenders who completed the
course of long-acting injectable naltrexone.
(3) Recidivism rates of eligible offenders to whom long-
acting injectable naltrexone was administered.
(4) The average amount of grants awarded to counties.
(5) The number of providers available to meet the
requirements provided in section 4603 (relating to county
participation requirements) on a county-by-county basis.
20150SB0524PN0471 - 4 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30